Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 31, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 1, 2026
DirectorOther
Context
Classification
other
Code J — not an open-market trade
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-25-047122
Filed / recorded
Jan 1, 2026, 7:00 AM UTC
Added to OQRO
Oct 6, 2026, 8:46 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Roivant Sciences Ltd.
Issuer CIK
1635088
Ticker
ROIV
Reporting person
Mayukh Sukhatme
Relationship
Director, Officer
Officer title
President & CIO
Security
Common Shares
Table
Non-derivative (Table I)
Transaction date
Dec 31, 2025
Transaction code
J
Shares / units
1,430,882
Price per share
$21.71
Acquired / disposed
Disposed (D)
Shares owned after
18,836,547
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
